A Phase 1b proof-of-concept clinical trial of YTX-7739 exploring multiple ascending doses in adult healthy volunteers and patients with Parkinson's Disease
Latest Information Update: 02 Jan 2023
At a glance
- Drugs YTX 7739 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Kineta; Yumanity Therapeutics
Most Recent Events
- 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
- 12 Aug 2021 According to a Yumanity Therapeutics media release, topline results from the Phase 1b part of the MAD study is expected in the fall of 2021.
- 22 Apr 2021 According to an Yumanity Therapeutics Media release, topline results from this study are expected in mid-2021.